Sixal Inc

Biotech · Private

LARI E59, a monoclonal antibody therapeutic for prevention of severe IgE-mediated food allergic reactions and mastocytosis

Grants
$3.3M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
6
2 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase II · Targeting surface-bound IgE as a novel allergy therapeutic$749,892
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase II · Targeting surface-bound IgE as a novel allergy therapeutic$1,489,545
Federal grantDepartment of Health and Human Services · Phase II · Targeting surface-bound IgE as a novel allergy therapeutic$739,653
Federal grantDepartment of Health and Human Services · Phase I · Safety and efficacy of an allergy therapeutic targeting FcERI bound IgE in human immune reconstituted mice.$286,656
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3134Engrail Therapeutics——
3135PHAGEPRO, INC.——
3136HTIC, INC.——
3137Sixal Inc——
3138Nirogyone Therapeutics LLC——
3139SEAK Therapeutics, LLC——
3140ALCAMENA STEM CELL THERAPEUTICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 6

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.